Milton-Edwards, formerly head of product and health solutions – Digital Health at Teva Pharmaceuticals, brings over 30 years of experience in pharma and healthcare technology. Prior to Teva ...

In this article, we are going to take a look at where Teva Pharmaceutical Industries Ltd (NYSE:TEVA) stands against the other stocks. A wave of selling gripped Wall Street this Friday, pushing ...

JERUSALEM, Dec 17 (Reuters) - (This Dec.17 story has been corrected to say the results were for ulcerative colitis, not for both the diseases, in paragraph 5) Teva and Sanofi said last year they ...

ADRs of Teva Pharmaceutical (NYSE:TEVA) and Sanofi (NASDAQ:SNY) traded higher in the premarket on Tuesday after the companies said that their experimental antibody therapy, duvakitug, reached the ...

With the new findings in hand, Sanofi and Teva are now plotting a phase 3 study for duvakitug, pending talks with regulators. Duvakitug hails from Teva’s labs, though Sanofi got in on the action ...

Duvakitug isn't just another drug in Teva's pipelineit's the drug. With consistent efficacy across patient groups and no major safety hiccups, this TL1A antibody therapy is now a frontrunner in ...

A Teva Pharmaceuticals drug being developed in partnership with Sanofi to hit a promising but competitive target for inflammation now has positive data from a clinical test in the two most common ...

Teva Pharmaceuticals’TEVA0.63%increase; green up pointing triangle shares soared and Sanofi’sSAN-0.33%decrease; red down pointing triangle stock moved higher following positive results from ...

Teva Pharmaceuticals' shares soared and Sanofi's stock moved higher following positive results from the latest trial of their jointly developed treatment for inflammatory bowel disease. The ...

Pharmaceuticals giant Pfizer closed Tuesday's session nearly 5% in the green, after it issued an upbeat full-year outlook for 2025. Pfizer guided to 2025 revenue of between $61bn (£48bn) and $64bn, ...

In the 14-week phase 2b study by Sanofi and Teva's U.S. affiliate held in the U.S., Europe and Israel, the drug, called duvakitug, showed that 36.2% of low dose and 47.8% of high dose patients ...